The Journal of Urology
Volume 183, Issue 6 , Pages 2193-2199 , June 2010

Association of Body Mass Index With Prostate Cancer Biochemical Failure

  • David Ly

      Affiliations

    • Cleveland Clinic Lerner College of Medicine of Case Western Reserve University, Cleveland, Ohio
    • Financial interest and/or other relationship with National Institutes of Health Clinical Research Training Program.
    • ,
  • Chandana A. Reddy

      Affiliations

    • Department of Radiation Oncology, Cleveland Clinic, Cleveland, Ohio
    • ,
  • Eric A. Klein

      Affiliations

    • Glickman Urological and Kidney Institute, Cleveland Clinic, Cleveland, Ohio
    • ,
  • Jay P. Ciezki

      Affiliations

    • Department of Radiation Oncology, Cleveland Clinic, Cleveland, Ohio
    • Corresponding Author InformationCorrespondence: Department of Radiation Oncology, Desk T28, 9500 Euclid Ave., Cleveland, Ohio 44195 (telephone: 216-445-9465; FAX: 216-445-1068)

Received 3 October 2009

References 

  1. Ogden CL, Carroll MD, Curtin LR, et al. Prevalence of overweight and obesity in the United States, 1999–2004. JAMA. 2006;295:1549
  2. Amling CL. Relationship between obesity and prostate cancer. Curr Opin Urol. 2005;15:167
  3. Wolk A, Mantzoros CS, Andersson SO, et al. Insulin-like growth factor 1 and prostate cancer risk: a population-based, case-control study. J Natl Cancer Inst. 1998;90:911
  4. Weiss JM, Huang WY, Rinaldi S, et al. IGF-1 and IGFBP-3: risk of prostate cancer among men in the Prostate, Lung, Colorectal and Ovarian Screening Trial. Int J Cancer. 2007;121:2267
  5. Rowlands MA, Gunnell D, Harris R, et al. Circulating insulin-like growth factor peptides and prostate cancer risk: a systematic review and meta-analysis. Int J Cancer. 2009;124:2416
  6. Weiss JM, Huang WY, Rinaldi S, et al. Endogenous sex hormones and the risk of prostate cancer: a prospective study. Int J Cancer. 2008;122:2345
  7. Massengill JC, Sun L, Moul JW, et al. Pretreatment total testosterone level predicts pathological stage in patients with localized prostate cancer treated with radical prostatectomy. J Urol. 2003;169:1670
  8. Ma J, Li H, Giovannucci E, et al. Prediagnostic body-mass index, plasma C-peptide concentration, and prostate cancer-specific mortality in men with prostate cancer: a long-term survival analysis. Lancet Oncol. 2008;9:1039
  9. Stroup SP, Cullen J, Auge BK, et al. Effect of obesity on prostate-specific antigen recurrence after radiation therapy for localized prostate cancer as measured by the 2006 Radiation Therapy Oncology Group-American Society for Therapeutic Radiation and Oncology (RTOG-ASTRO) Phoenix consensus definition. Cancer. 2007;110:1003
  10. Palma D, Pickles T, Tyldesley S, et al. Obesity as a predictor of biochemical recurrence and survival after radiation therapy for prostate cancer. BJU Int. 2007;100:315
  11. Strom SS, Kamat AM, Gruschkus SK, et al. Influence of obesity on biochemical and clinical failure after external-beam radiotherapy for localized prostate cancer. Cancer. 2006;107:631
  12. Siddiqui SA, Inman BA, Sengupta S, et al. Obesity and survival after radical prostatectomy: a 10-year prospective cohort study. Cancer. 2006;107:521
  13. Freedland SJ, Aronson WJ, Kane CJ, et al. Impact of obesity on biochemical control after radical prostatectomy for clinically localized prostate cancer: a report by the Shared Equal Access Regional Cancer Hospital database study group. J Clin Oncol. 2004;22:446
  14. Magheli A, Rais-Bahrami S, Trock BJ, et al. Impact of body mass index on biochemical recurrence rates after radical prostatectomy: an analysis utilizing propensity score matching. Urology. 2008;72:1246
  15. Motamedinia P, Korets R, Spencer BA, et al. Body mass index trends and role of obesity in predicting outcome after radical prostatectomy. Urology. 2008;72:1106
  16. van Roermund JG, Kok DE, Wildhagen MF, et al. Body mass index as a prognostic marker for biochemical recurrence in Dutch men treated with radical prostatectomy. BJU Int. 2009;104:321
  17. Efstathiou JA, Bae K, Shipley WU, et al. Obesity and mortality in men with locally advanced prostate cancer: analysis of RTOG 85-31. Cancer. 2007;110:2691
  18. Simone NL, Singh AK, Cowan JE, et al. Pretreatment predictors of death from other causes in men with prostate cancer. J Urol. 2008;180:2447
  19. National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology™: Prostate Cancer V: 2.2009. http://www.nccn.org/professionals/physician_gls/f_guidelines.aspAccessed September 25, 2009
  20. Charlson ME, Pompei P, Ales KL, et al. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis. 1987;40:373
  21. Greene FL, Page DL, Fleming ID, et al. AJCC Cancer Staging Manual. 6th ed.. New York: Springer; 2002;
  22. Jayachandran J, Banez LL, Aronson WJ, et al. Obesity as a predictor of adverse outcome across black and white race. Cancer. 2009;115:5263
  23. Banez LL, Hamilton RJ, Partin AW, et al: Obesity-related plasma hemodilution and PSA concentration among men with prostate cancer. JAMA 298: 2275.
  24. Litman HJ, Bhasin S, Link CL, et al. Serum androgen levels in black, Hispanic, and white men. J Clin Endocrinol Metab. 2006;91:4326
  25. Evans S, Metcalfe C, Ibrahim F, et al. Investigating Black-White differences in prostate cancer prognosis: a systematic review and meta-analysis. Int J Cancer. 2008;123:430
  26. Sarma AV, Dunn RL, Lange LA, et al. Genetic polymorphisms in CYP17, CYP3A4, CYP19A1, SRD5A2, IGF-1, and IGFBP-3 and prostate cancer risk in African-American men: the Flint Men's Health Study. Prostate. 2008;68:296
  27. Isaacs SL, Schroeder SA. Class—the ignored determinant of the nation's health. N Engl J Med. 2004;351:1137
  28. Roach M, Hanks G, Thames H, et al. Defining biochemical failure following radiotherapy with or without hormonal therapy in men with clinically localized prostate cancer: recommendations of the RTOG-ASTRO Phoenix Consensus Conference. Int J Radiat Oncol Biol Phys. 2006;65:965
  29. Stephenson AJ, Kattan MW, Eastham JA, et al. Defining biochemical recurrence of prostate cancer after radical prostatectomy: a proposal for a standardized definition. J Clin Oncol. 2006;24:3973
  30. Harris R, Lohr KN. Screening for prostate cancer: an update of the evidence for the U.S. Preventive Services Task Force. Ann Intern Med. 2002;137:917

 Study received institutional review board approval.

PII: S0022-5347(10)00251-X

doi: 10.1016/j.juro.2010.02.010

The Journal of Urology
Volume 183, Issue 6 , Pages 2193-2199 , June 2010

Article Tools

* Image Usage & Resolution